, Volume 58, Supplement 2, pp 291–292 | Cite as

Once-Daily Oral Trovafloxacin in the Treatment of Diabetic Foot Infections

Results of an Open-Label, Noncomparative, Multicentre Trial
  • R. Daniel
  • the Trovafloxacin Study Group
Poster Presentations Extended Abstract


  1. 1.
    Swartz MN. Skin and soft tissue infections. In: Mandell GL, Bennett J, Dolan R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995: 909–29Google Scholar
  2. 2.
    Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39 Suppl. B: 43–9PubMedCrossRefGoogle Scholar
  3. 3.
    Spangler SK, Jacobs MR, Appelbaum PC. Susceptibility of anaerobic bacteria to trovafloxacin: comparison with other quinolones and non-quinolone antibiotics. Infect Dis Clin Pract 1996; 5 Suppl. 3: S101–9CrossRefGoogle Scholar
  4. 4.
    Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385–94PubMedCrossRefGoogle Scholar
  5. 5.
    Vincent J, Teng R, Dogolo LC, et al. Trovafloxacin and of loxacin profiles in ambulatory subjects matched for age and gender. Proceedings of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996; A6: 2Google Scholar
  6. 6.
    Taylor A, Swan S, Marbury T, et al. The effect of varying degrees of renal impairment on the safety, toleration and pharmacokinetics of trovafloxacin. Proceedings of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, Ontario. Washington DC: American Society for Microbiology, 1997; A66: 14Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • R. Daniel
    • 1
  • the Trovafloxacin Study Group
  1. 1.Pfizer Central ResearchPfizer LimitedSandwichEngland

Personalised recommendations